Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP-745 in Atherosclerosis Cardiovascular Disease
NCT07303777Phase 2Recruiting
- Sponsor
- Atom Therapeutics
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ABP-745 in atherosclerotic cardiovascular disease (ASCVD) (4 arms), sponsored by Atom Therapeutics. Primary endpoint: Percent Atheroma Volume at 52 weeks. Started Apr 2026; status: recruiting.
02
Drugs
ABP-745
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT07303777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303777.